Physician profile
Bethany Bowman
NPI 1518601277
$2,072.67
in general payments reported to CMS, 2019-2025
14 companies · $1,531 in 2025
The $1,531 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.02 · 2024: $524 · 2025: $1,531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $487.72 | 2024-2025 | Jemperli, Zejula |
| Abbvie INC. | $404.03 | 2024-2025 | |
| Eisai INC. | $337.52 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $311.60 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Caris Mpi, INC. | $181.87 | 2025 | Mi Cancer Seek |
| Myriad Genetic Laboratories, INC. | $86.41 | 2024-2025 | Myrisk, Precisetumor |
| Baxter Healthcare | $51.08 | 2024-2025 | Perclot |
| Pfizer INC. | $39.44 | 2025 | |
| Astellas Pharma US INC | $36.44 | 2025 | Veozah |
| Verastem, INC. | $33.34 | 2025 | Avmapki Fakzynja Co-Pack |
| Accord Healthcare, INC. | $29.39 | 2025 | |
| Daiichi Sankyo INC. | $28.80 | 2024 | Enhertu |
| Dilon Technologies, INC. | $28.01 | 2025 | Hemoblast Bellows |
| Ambu INC. | $17.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.